AntriaBio

Financials

Investors

Financials

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Jun. 30, 2017
Current assets    
Cash $ 4,015,715 $ 4,486,538
Other current assets 349,170 442,015
Total current assets 4,364,885 4,928,553
Non-current assets    
Fixed assets, net 5,064,604 5,325,401
Intangible assets, net 42,499 44,322
Deferred lease asset 80,562 86,293
Deposits 244,341 244,341
Total non-current assets 5,432,006 5,700,357
Total Assets 9,796,891 10,628,910
Current liabilities:    
Accounts payable and accrued expenses 1,568,041 1,652,677
Convertible notes payable 10,000 10,000
Deferred lease liability, current portion 110,765 105,295
Interest payable 2,762 2,762
Warrant derivative liability 246 588
Total current liabilities 1,691,814 1,771,322
Non-current liabilities:    
Deferred lease liability, less current portion 274,130 304,575
Deposit liability 25,046 25,046
Total non-current liabilities 299,176 329,621
Total Liabilities 1,990,990 2,100,943
Commitments and Contingencies (Note 10)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 53,728,640 and 49,228,640 shares issued and outstanding, September 30, 2017 and June 30, 2017 53,730 49,230
Additional paid-in capital 78,758,745 72,800,699
Accumulated deficit (71,006,574) (64,321,962)
Total stockholders’ equity 7,805,901 8,527,967
Total Liabilities and Stockholders’ Equity $ 9,796,891 $ 10,628,910
v3.8.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Research and development    
Compensation and benefits $ 1,500,864 $ 1,303,840
Consultants and outside costs 130,361 271,475
Material manufacturing costs 426,089 511,707
Clinical trial costs 979,766 0
License costs 770,900 0
Facilities and other costs 502,657 398,907
Research and development 4,310,637 2,485,929
General and administrative    
Compensation and benefits 1,795,427 866,901
Professional fees 223,594 146,151
Investor relations 59,871 68,107
General and administrative 327,600 256,596
General and administrative 2,406,492 1,337,755
Total operating expenses 6,717,129 3,823,684
Loss from operations (6,717,129) (3,823,684)
Other income (expense)    
Interest income 337 0
Rent income 31,838 0
Interest expense 0 (1,595)
Derivative gains 342 9,412
Total other income 32,517 7,817
Net loss $ (6,684,612) $ (3,815,867)
Net loss per common share - basic and diluted $ (0.13) $ (0.11)
Weighted average number of common shares outstanding - basic and diluted 52,887,981 35,400,427
v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net Loss $ (6,684,612) $ (3,815,867)
Amortization of intangible asset 1,823 1,823
Depreciation expense 266,613 268,355
Stock-based compensation expense 1,507,699 889,028
Derivative gains (342) (9,412)
Warrant expense 14,847 0
Changes in operating assets and liabilities:    
Decrease in other assets 92,845 362
Decrease in deferred lease asset 5,731 0
Decrease in accounts payable and accrued expenses (84,636) (273,637)
Increase in interest payable 0 500
Decrease in deferred lease liability (24,975) (29,462)
Net Cash Used In Operating Activities (4,905,007) (2,968,310)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (5,816) (126,956)
Return of security deposit 0 65,933
Net Cash Used In Investing Activities (5,816) (61,023)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on lease payable 0 (23,128)
Proceeds from issuance of equity financing 4,500,000 2,692,399
Payment of placement agent compensation and issuance costs (60,000) (336,211)
Net Cash Provided by Financing Activities 4,440,000 2,333,060
Net decrease in cash (470,823) (696,273)
Cash - Beginning of Period 4,486,538 4,062,013
Cash - End of Period 4,015,715 3,365,740
Cash Paid During the Period for:    
Taxes 0 0
Interest 0 0
Non-Cash Transactions:    
Fixed assets acquired through accounts payable and accrued expenses $ 0 $ 59,028